EUVIMEDEUVIMED entdecken
Crossref

Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist

Rose Mary Attieh, Pratap Upadrista, Anna T Levy, Kenar D Jhaveri

Clinical Nephrology · 2025

DOI: 10.5414/cn111488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Rose Mary Attieh und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hyperphosphatemia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperphosphatemiaHumansMaleFemaleAgedMiddle AgedReceptors, Fibroblast Growth FactorIncidenceAntineoplastic AgentsPyrazolesRetrospective StudiesAged, 80 and overProtein Kinase InhibitorsQuinoxalines

Substanzen

Receptors, Fibroblast Growth FactorAntineoplastic AgentserdafitinibPyrazolesProtein Kinase InhibitorsQuinoxalines

Zitieren

APA

Attieh, R. M., Upadrista, P., Levy, A. T., & Jhaveri, K. D. (2025). Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist. Clinical Nephrology. https://doi.org/10.5414/cn111488

Vancouver

Attieh RM, Upadrista P, Levy AT, Jhaveri KD. Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist. Clinical Nephrology. 2025. doi:10.5414/cn111488

BibTeX
@article{Attieh2025,
  author = {Attieh, Rose Mary and Upadrista, Pratap and Levy, Anna T and Jhaveri, Kenar D},
  title = {Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist},
  journal = {Clinical Nephrology},
  year = {2025},
  doi = {10.5414/cn111488}
}
Kostenlos starten →